Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apotea AB (publ)CHIX:APOTES 18 3-Year EBITDA Growth Rate is 64.20% as of Jun. 2026, which is 36% above its 10-year median of 47.15. GuruFocus rates CHIX:APOTES with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 526 Healthcare Providers & Services companies, Apotea AB (publ) ranks better than 94.87% on this metric.
During the past 12 months, Apotea AB (publ)'s average EBITDA Per Share Growth Rate was 13.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 64.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Apotea AB (publ) was 64.20% per year. The lowest was 30.10% per year. And the median was 47.15% per year.
Apotea AB (publ) (CHIX:APOTEs) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Apotea AB (publ) 3-Year EBITDA Growth Rate Related Terms
Apotea AB (publ) 3-Year EBITDA Growth Rate Competitor Comparison
For the Pharmaceutical Retailers subindustry, Apotea AB (publ)'s 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apotea AB (publ) 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Apotea AB (publ)'s 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Apotea AB (publ)'s 3-Year EBITDA Growth Rate falls into.
Apotea AB (publ) 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 64.20% mean?
Apotea AB (publ) (CHIX:APOTES) has a 3-Year EBITDA Growth Rate of 64.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Apotea AB (publ) and its competitors. This is 36% above median its historical median of 47.15. Over the past decade, Apotea AB (publ)'s 3-Year EBITDA Growth Rate has ranged from 30.10 to 64.20. According to the industry distribution chart, Apotea AB (publ) ranks #27 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 5.1%.
Is Apotea AB (publ)'s 3-Year EBITDA Growth Rate too high?
Apotea AB (publ)'s current 3-Year EBITDA Growth Rate of 64.20% is 36% above median its 10-year median of 47.15. Over the past 10 years, this metric has ranged from a low of 30.10 to a high of 64.20. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Apotea AB (publ)'s value of 64.20% is 529.4% above this industry median. Based on the distribution chart, Apotea AB (publ) ranks #27 out of 526 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Apotea AB (publ) has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Apotea AB (publ)'s 3-Year EBITDA Growth Rate compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Apotea AB (publ) ranks #27 out of 526 companies for 3-Year EBITDA Growth Rate. This places Apotea AB (publ) in the top 5% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 10.20. Apotea AB (publ)'s value of 64.20% is 529.4% above this benchmark. Historically, Apotea AB (publ)'s own 3-Year EBITDA Growth Rate has ranged from 30.10 to 64.20 over the past decade. While the company's 10-year median is 47.15 vs. the industry median of 10.20, Apotea AB (publ) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apotea AB (publ)'s current 3-Year EBITDA Growth Rate of 64.20% is 529.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Apotea AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apotea AB (publ)'s current 3-Year EBITDA Growth Rate is 64.20%, which is 36% above median its own 10-year median of 47.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apotea AB (publ) stock overvalued right now?
Apotea AB (publ) (CHIX:APOTES) has a current 3-Year EBITDA Growth Rate of 64.20%. The current 3-Year EBITDA Growth Rate is 64.20%, which is 36% above median its 10-year median of 47.15 and 529.4% above the Healthcare Providers & Services industry median of 10.20. Apotea AB (publ)'s overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Apotea AB (publ) (CHIX:APOTES), the current 3-Year EBITDA Growth Rate is 64.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.
18GF Score
Get the complete analysis for CHIX:APOTES
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:APOTES has been successfully added to your 
